occur in older patients where the potential for drug-drug interaction is higher and in patients with advanced-phase disease. Adverse reactions can usually be managed with either a reduction of the dose or an interruption of treatment along with appropriate supportive measures (concomitant growth factor therapy, diuretics, antiemetics, etc.). [3] [4] [5] However, in rare cases permanent cessation of therapy is the only solution to manage the intolerant patient. 6 
Imatinib Resistance
Several point mutations within the Abl-kinase protein have been reported that can mediate resistance to imatinib. 7 Of these mutations, the gatekeeper T315I mutation is the most clinically relevant. [8] [9] [10] [11] Amplification of BCR-ABL may account for resistance to imatinib in a small percentage of cases, and these patients may or may not respond to increased doses of the drug. 7, 12 Activation of other signaling pathways such as the Src family of kinases (SFKs), 13 the presence of p-glycoprotein efflux pumps through MDR-1 gene expression, 14 and plasma binding of α-1 acid glycoprotein 15 with imatinib are other less important mediators of resistance. Given the new unmet needs in CML that emerged following the use of imatinib, investigators began to explore the development of new compounds to overcome imatinib resistance. It is against this background that nilotinib was conceived (see Figure 1 ).
assessing the safety and tolerability of nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive (Ph + ) acute lymphoblastic leukemia (ALL). The larger phase II protocol included six arms: three of these arms involved patients with imatinib failure in CP, AP, and BP CML, [16] [17] [18] another arm involved patients with imatinib and/or dasatinib failure, a further arm involved patients with imatinib/dasatinib failure in AP and blastic crisis, and the remaining arm included patients with Ph + ALL and rarer disorders such as systemic mastocytosis. All of the trials included patients who had previously received imatinib therapy but were either resistant to or intolerant of the treatment.
While nilotinib has been initially developed as a second-line therapy, it is also being evaluated for use in the first-line setting. The Italian GIMEMA CML Working Party study includes treatment-naïve adult patients with CML in early CP (CP-CML). 19 Initial data for 73 previously untreated patients with early CP-CML show that the complete hematological response (CHR) rate after three-month treatment with nilotinib 400mg twice-daily (BID) was 100%. Of 48 patients who completed six months of therapy, the CHR was 98%. The complete cytogenic response (CCyR) rate was 78 and 96% at three and six months, respectively. One patient had progressive disease at six months. The ongoing MD Anderson Cancer Center study includes patients with untreated CP-CML or with <1 month of therapy with imatinib, 20 and also involves a small cohort of patients with previously untreated AP-CML.
Safety and Tolerability
The primary objectives of the phase I study were to determine the safety and tolerability of nilotinib and to characterize its biological and pharmacokinetic profiles. 21 Hematological and cytogenetic responses were evaluated as secondary end-points. The trial recruited 119 patients (106 with Ph + CML and 13 with Ph + ALL). The most common toxicities observed were mild to moderate skin rashes, transient and clinically insignificant hyperbilirubinemia, and myelosuppression.
Grade 3/4 neutropenia occurred in 9% of patients who received the nilotinib 400mg BID dose and in 22% of patients who received the 600mg BID dose. 21 In the larger phase II trial, nilotinib-treated patients with CP-CML and who were resistant to or intolerant of imatinib were evaluable for safety and tolerability. 16, 22 The study showed a similar toxicity profile to that observed compared in the phase I study. The most frequent grade 3 or 4 hematological toxicities reported were neutropenia (30%) and 
Of the non-hematological toxicities observed, the most common were rash, nausea, pruritus, headache, and fatigue. Among the biochemical anomalies noted, almost all were not associated with any clinical sequelae. Prolongation of the QT interval (by over 500msec) from baseline was seen in ≤1% of cases. Most of these toxicities occurred within the first three to six months of therapy. 22 Notable AEs related to fluid retention that have been associated with other BCR-ABL inhibitors, such as pleural effusions (17%) and edema (29-72%), were not commonly seen in patients participating in this study. 16 Safety and tolerability data from the other phase II studies were broadly similar to the CP data. were headache, rash, and nausea. In a subgroup analysis of this population, nilotinib was shown to be highly active in patients who had failed on imatinib and dasatinib therapy.
Cross-intolerance between imatinib and nilotinib was shown to be negligible, with only 1% recurrence of non-hematological grade 3/4 AEs associated with imatinib intolerance and 18% discontinuation of nilotinib therapy due to similar grade 3/4 hematological AEs seen with imatinib.
25,26
All of these AEs were thrombocytopenia and were only reported in CP patients. It should be noted that cross-intolerance means that an AE seen with imatinib is not seen in the same patient taking nilotinib. Nilotinib also showed marked efficacy in 59 (63%) imatinib-intolerant CML-CP patients and 10 (40%) imatinib-intolerant CML-AP patients with MCyR during nilotinib therapy. These results reflect the more effective targeting of BCR-ABL by nilotinib (see Figure 1) . 25, 26 A summary of intolerance to nilotinib observed in imatinib-intolerant patients in a study including 321 patients with CML-CP and 136 with CML-AP 26 for non-hematological AEs is given in Table 1 , and for hematological AEs in the same study in Table 2 .
Efficacy Data
Efficacy data are available from the phase I trial 21 and the three phase II studies [16] [17] [18] conducted in patients with CP, AP, and BP CML, as well as a nilotinib third-line phase II trial in patients with both imatinib and dasatinib Open-label, CML-AP: 9 13 no baseline CHR: 2 (22%) returned to CP, 6 (67%) were not evaluable, and there was 1 death (11%). failure. A summary of phase I/II efficacy data supporting the use of nilotinib in CML patients who have failed on imatinib is given in Table 3 .
Phase I Trial
In this study, 11 of 17 patients (65%) with CML-CP produced a CHR in response to treatment with nilotinib. 21 The treatment provided major cytogenetic remission in six patients (35%), and partial cytogenetic remission (classified as minimal, major, or minor) occurred in nine patients (53%). A further group in the study had CML-AP (n=56), of whom 26 (46%)
showed a CHR and 15 (27%) showed a major cytogenetic response (MCyR).
Among the total population, 38 (74%) had hematological remissions had a CHR, one returned to CP (6%), five had stable disease (29%), four (24%) were not evaluable, and four (24%) had progressive disease.
Conclusions and Future Directions
Nilotinib is currently being evaluated as a first-line option and has proved to be optimal second-line therapy in CML based on:
• its clinical efficacy;
• its minimal cross-intolerance with imatinib;
• its activity against some relevant mutations (except for T315I);
• its low incidence of grade 3/4 extramedullary AEs, which tend to occur early in therapy; and
• its relatively low incidence of severe myelosuppressive AEs.
Phase III studies are under way in patients with newly diagnosed CML, in which the goal of treatment will be to obtain improved responses over the current standard of care, imatinib. The rapid progression of nilotinib through the regulatory process represents a true triumph of rational anticancer agent design and builds on the expectations raised by the enormous success of imatinib in the clinic. n
